Trends in Phase II Trials for Cancer Therapies
<i>Background</i>: Drug combinations are the standard of care in cancer treatment. Identifying effective cancer drug combinations has become more challenging because of the increasing number of drugs. However, a substantial number of cancer drugs stumble at Phase III clinical trials desp...
Main Authors: | Faruque Azam, Alexei Vazquez |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/2/178 |
Similar Items
-
Interpreting a Bayesian phase II futility clinical trial
by: Jonathan Beall, et al.
Published: (2022-11-01) -
A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis
by: John A. Tayek, et al.
Published: (2022-12-01) -
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma
by: Merve Hasanov, et al.
Published: (2020-08-01) -
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials
by: Goffin John R, et al.
Published: (2011-12-01) -
Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
by: Dionysios Palermos, et al.
Published: (2022-12-01)